Lantern Pharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lantern Pharma Inc. on November 22, 2021. The registrant is a Delaware corporation with principal executive offices in Dallas, Texas, and its common stock trades on The Nasdaq Stock Market under the symbol "LTRN". The company is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a corporate action regarding a share repurchase program.
Material Changes
On November 22, 2021, the Company announced the initiation of a share repurchase program. This announcement is the primary material event reported in this filing.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) detailing the share repurchase program. The text explicitly states that the information in Item 8.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference in other filings unless expressly stated. No specific financial guidance, risk factors, or contingencies are detailed within the body of this 8-K text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific details on the share repurchase program, including authorization amount, duration, and execution methods.
- Verify the current share count and market price to assess the potential impact of the repurchase program.
- Check subsequent filings for updates on the execution of the repurchase program.
- Confirm the company's liquidity position in the most recent 10-Q or 10-K to evaluate its ability to fund the repurchases.